Purpose. Gene transfer to the ocular surface epithelium holds the potential for therapy and delivery of therapeutic proteins to the surface epithelium. We determined whether a reporter gene can be introduced into ocular surface epithelium in vitro, ex vivo and in vivo using a recombinant replication-deficient adenovirus. Methods. Adenovirus vector containing the reporter gene of lacZ (1.3 to 2.0X104 PFU) was added to the culture medium of human corneal and conjunctival cell lines. The ex vivo study used human corneal and conjunctival tissues obtained in surgery. In vivo study, adenovirus vector (5 X 105 PFU, 1.5-3.0 μl) was applied topically to the eyes of 7 week-old cotton rats (all female, N=14), which were enucleated at 24 and 48 hours after application. Results. The lacZ expression was demonstrated in corneal epithelium cell line at day 2 (8.0X102 or more PFU) and conjunctival cell line (8.0X102 or less PFU) until day 7, as well as ex vivo study. Conjunctival epithelium showed the cell toxity with 4.0X103 or more PFU, however no side effects were observed in corneal epithelium. In vivo study, only the conjunctival epithelium was positive for β-Gal activity at 24 and 48 hours after topical application. Conclusions. Adenovirus vectors are capable to direct delivery of genes to the corneal and conjunctival epithelium with different optimal concentration without toxicity, suggesting a variety of possible gene therapy application.
|ジャーナル||Investigative Ophthalmology and Visual Science|
|出版ステータス||Published - 1996 2 15|
ASJC Scopus subject areas